Company ProfilePremium

Sabinsa Corporation

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Sabinsa Corporation - Food & Beverages showcase

Year Founded & Workforce

1988

1,400 Employees

Industry

Food & Beverages

Services

Probiotics
Sabinsa Corporation logo

Sabinsa Corporation Employee Contacts

20 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Sabinsa Corporation Overview

Sabinsa Corporation is the US commercial and marketing arm of the Sami-Sabinsa Group, a vertically integrated Indian-American health-science company that pioneered the commercialisation of standardised Ayurvedic botanical extracts in Western dietary-supplement markets. Founded in New Jersey in 1988 by pharmacist-entrepreneur Dr. Muhammed Majeed, Sabinsa built its franchise on branded, patented and clinically studied ingredients — most notably Curcumin C3 Complex®, BioPerine® black-pepper extract, Boswellin®, ForsLean® and the probiotic LactoSpore® — sold to supplement, functional-food, cosmetic and pharmaceutical manufacturers. The group markets more than 120 standardised botanical extracts, operates eleven manufacturing facilities, supports an approximately 20,000-acre cultivation programme, and derives about 95% of its business from exports. Since 2025, Sabinsa has extended downstream into finished consumer products through its Sabinsa Wellness division. It competes as a science-and-IP-led premium supplier against both global ingredient majors and low-cost Indian and Chinese extract producers.


What the company does

Sabinsa describes itself as a multinational health-science company that manufactures, supplies and markets herbal extracts, cosmeceuticals, minerals, dietary-supplement ingredients and specialty fine chemicals for the nutritional, cosmetic, pharmaceutical and food industries [S2]. Its current self-description lists botanical extracts, nutraceutical and cosmeceutical ingredients, probiotics, minerals and enzymes [S1].

Because Sabinsa is private, there is no annual-report business description. The company's recurring press-release boilerplate positions it as known for "sustainable, natural, well-researched ingredients," with emphasis on clinical substantiation, chain of custody and sustainable sourcing [S17][S20].

Business model

Business lineModelCustomerEvidence
Branded ingredients (core)B2B product sales of patented/trademarked standardised extracts, probiotics, enzymesSupplement brands, contract manufacturers, functional food & beverage makers[S1][S20]
Cosmeceutical ingredients (Sabinsa Cosmetics)B2B product salesPersonal-care and cosmetic formulators[S22]
Contract manufacturing (Utah)Fee/product manufacturing for third-party brandsSupplement brand owners[S29][S17]
Finished consumer products (Sabinsa Wellness)B2C/B2B2C via retailNatural-products retailers, consumers[S18][S19]
IP licensingLicensing of patents/trademarks; litigation settlements converted to licences (e.g., Chemill)Ingredient companies[S24]
API / fine chemicals (group, India)Product sales of active pharmaceutical ingredientsPharma companies[S26]

Revenue mix: The split between product, service (contract manufacturing) and licensing revenue is not publicly disclosed. Independent characterisation: the overwhelming majority of revenue is product sales of ingredients; contract manufacturing and consumer products are small but strategically growing; licensing income is likely immaterial.

Value-chain position

Sami-Sabinsa is unusually vertically integrated for an ingredient company. It spans: (1) contract cultivation of raw botanicals on approximately 20,000 acres [S7]; (2) procurement (including a spice procurement division, Sami Spices, established in Cochin in 1999) [S5]; (3) extraction, fermentation and synthesis at eleven group manufacturing facilities [S5]; (4) R&D and clinical trials with 120+ senior scientists [S5]; (5) IP creation and enforcement; (6) global marketing through Sabinsa entities in the US, Europe, China, Australia and elsewhere; and (7) since 2025, finished-goods brands [S18].

Customer types and end-markets

  • Dietary-supplement brand owners and contract manufacturers (core)

  • Functional food and beverage manufacturers — many Sabinsa ingredients hold GRAS status [S17]

  • Cosmetic and personal-care formulators (e.g., Babchiol™, SabiWhite®, LactoSporin™) [S22]

  • Pharmaceutical companies (APIs from the Hassan facility) [S26]

  • Sports and active-nutrition brands (2026 focus) [S1]

  • Retailers and consumers (Sabinsa Wellness) [S18]

Independent characterisation: Sabinsa is a mid-sized, family-controlled, export-oriented botanical-ingredient specialist whose differentiation rests on brand equity, patent density and published clinical evidence rather than scale or price. Its strategic challenge is defending premium pricing against commoditised curcumin, ashwagandha and probiotic supply, which management itself acknowledges [S14].

Strategy

No annual report or investor day exists. Strategic themes are reconstructed from management statements.

Stated themes:

  1. Science-led premium positioning. Management describes a long-cycle process: identifying phytonutrients, isolating actives, safety/toxicology evaluation, standardised extraction and heavy clinical investment [S34].

  2. Downstream integration into consumer brands. The Nature's Formulary deal was framed as a milestone in a long-term strategy to strengthen leadership in natural products, giving Sabinsa direct consumer reach [S12][S13].

  3. Manufacturing capacity expansion. Hassan facility and stated intent to build on group manufacturing capability [S8][S26].

  4. US market expansion. Explicitly cited by the CEO in 2026 hiring announcements [S31].

  5. Category focus. 2026 emphasis on metabolic health, women's health, longevity, liver health and active nutrition [S1][S17][S37].

  6. AI-enabled clinical evidence generation. CEO's 2026 Vitafoods Asia panel on AI-driven clinical trials [S21].

  7. Partnerships. CEO said in 2024 that he sees more partnerships ahead [S8].

Initiatives in the last 24 months (Oct 2024 – Oct 2026):

Medium-term financial targets: Not publicly disclosed. The only quantified historical ambition was the founder's 2020 expectation that Hassan would help double group revenue [S26] and the 2022 IPO intention [S10].

Products & Services

The group markets more than 120 standardised botanical extracts [S5][S12]. The catalogue below covers flagship branded ingredients named in company and trade sources. Pricing is not publicly disclosed for any B2B ingredient.

Nutraceutical ingredients

BrandDescription / source materialKey positioningSource
Curcumin C3 Complex®Standardised curcuminoids from turmericDescribed by company as the most clinically researched curcumin ingredient; patent-protected and litigated[S17][S25]
Curcumin C3 Reduct®Tetrahydrocurcuminoids (curcumin metabolites)Oral health, antioxidant; EFSA-approved / REACH-registered form for cosmetics[S20][S22][S33]
BioPerine®Black-pepper (piperine) extractBioavailability enhancer; flagship brand[S4][S20]
Boswellin®Boswellia serrata extractJoint health[S4]
ForsLean®Coleus forskohlii extractWeight management/body composition[S4]
Shagandha™Ashwagandha extractStress/adaptogen[S4][S20]
Saberry®Amla (Emblica officinalis) extractAntioxidant, metabolic health; used in Sanutra products[S4][S17]
Sabeet®Beetroot extractNitric oxide/active nutrition; 2026 trial in postmenopausal women[S1][S3x]
LactoSpore®Bacillus coagulans spore probioticGut health; Best Technology Innovation award, ChengDu[S4]
DigeZyme®Multi-enzyme complexDigestive support[S20]
Sabroxy®Oroxylum indicum extractCognitive support[S20]
Nigellin®Black-seed (Nigella sativa) extractImmune/metabolic[S20]
LivLonga®Combination of two clinically studied ingredientsLiver support; preclinical-to-clinical programme[S20][S34]
Silbinol®Pterostilbene-based ingredientHealthy ageing; used in Sanutra[S17]
pTeroSol®Water-soluble Pterocarpus marsupiumBlood-sugar management[S35]
NiLitis®Joint-health ingredientJoint support[S35]
Macumax®Eye-health ingredientEarly dry-type AMD study (40 subjects, 90 days, open-label)[S36]
Cococin®Coconut-water-derived ingredientFeatured at SAPHEX 2026[S3x]
PoZibio®Postbiotic ingredientFeatured at SAPHEX 2026[S3x]
Picroliv®Picrorhiza kurroa extractLiver support; featured in Nature's Formulary[S20]

[S3x] = sabinsa.com SAPHEX 2026 event page (see source list S37).

Cosmeceutical ingredients

BrandDescriptionSource
LactoSporin™Postbiotic for skin renewal[S22]
Cosmoperine®Tetrahydropiperine penetration enhancer[S4]
Babchiol™Retinol alternative, ≥99% bakuchiol from Psoralea corylifolia[S22]
SabiWhite®Tetrahydrocurcuminoid skin-brightening active[S22]
pTeroWhite®Pterocarpus-derived brightening ingredient[S22]
Artonox®Antioxidant cosmetic active[S22]

Consumer brands (Sabinsa Wellness)

BrandPositioningFlagship contentSource
America's Finest, Inc. (AFI)Science-based supplementsCurcumin C3 Complex products[S17][S20]
Sanutra WellnessHealthy ageing / baby-boomer demographicSaberry, Silbinol formulations[S17]
Nature's FormularyPremium Ayurvedic products (founded c.1993)Ashwagandha, Picrorhiza/Picroliv[S18][S20]

All Wellness products are made in the USA at the Utah contract-manufacturing facility [S17].

Services

ServiceDescriptionSource
Contract manufacturingFinished dosage manufacturing in Utah[S17]
Regulatory/dossier supportFull safety, toxicology, clinical and specification dossiers per ingredient; country-specific regulatory guidance[S21][S34]
EducationWeb seminars (e.g., LactoSpore, weight management), "Sabinsa on Wheels" (South Korea), Knowledge Days (Paris 2026)[S10b][S37]

Financial Narrative

Disclosure status: Sabinsa Corporation and Sami-Sabinsa Group Limited do not publish audited financial statements in the public domain. The only management-disclosed figure is group revenue "over ₹1,200 crore" for FY2022 [S10]. All other cells are left blank (not publicly disclosed).

Income statement: notes and sources

Note: FY2022 figure is "over ₹1,200 crore" (₹12,000 million) per founder interview, The Hindu BusinessLine, 14 Jul 2022 [S10]; treat as a floor, not an audited number.

Disclosed capital investment

Separately, in July 2022 the group cited a ₹300 crore (₹3,000 million) investment in two manufacturing facilities [S10]. Whether this overlaps the US$30M Hassan figure is not disclosed.

Commentary

In the absence of audited financials, analysis is necessarily qualitative. Three inferences are reasonably supported. First, scale: at roughly ₹1,200 crore (~US$155–160M) in FY2022, the group is a mid-sized specialist — an order of magnitude smaller than diversified ingredient majors such as Givaudan or Kerry. Second, capital intensity rose meaningfully in FY2020–FY2023 with the Hassan greenfield build, which the founder expected would help "double" revenue [S26]; no subsequent disclosure confirms whether that trajectory materialised. Third, the business is structurally export-dependent (~95% exports) [S10], meaning reported INR revenue benefits from rupee depreciation against the dollar and euro, while US tariff and regulatory changes are direct exposures. Revenue CAGR cannot be computed. The 2022 statement that an IPO was "underway in the next two years" [S10] has not, to our knowledge, resulted in a DRHP filing with SEBI; the founder's death in March 2024 and leadership transition are plausible reasons for deferral, but the company has not stated this.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRoleLocation

Sami-Sabinsa Group Limited (formerly Sami Labs Ltd)

Parent; R&D; manufacturing

Bengaluru, India

Sabinsa Corporation

US marketing, sales, scientific affairs

East Windsor, NJ

Sabinsa Utah (contract manufacturing)

Finished-goods manufacturing; Sabinsa Wellness production

Payson, Utah

Sabinsa Wellness (consumer goods division)

America's Finest Inc. (AFI), Sanutra Wellness, Nature's Formulary

US

Sabinsa Cosmetics

Cosmeceutical ingredients

NJ-based division

Sami Nutraceuticals Pvt. Ltd.

Hassan greenfield facility (Unit-1)

Hassan, India

Sami Spices

Spice procurement and marketing

Cochin, India

Sabinsa Nanjing Biotechnology Co. Ltd.

China operations

Nanjing, China

Sabinsa Europe (incl. France, Poland, UK offices)

European sales

Europe

Sabinsa Australia

Australia/NZ sales; TGA listings

Australia

Segment (Analyst-defined) Overview

Segment (analyst-defined)ContentsRevenue disclosed?

Nutraceutical ingredients

Botanical extracts, probiotics, enzymes, minerals

No

Cosmeceutical ingredients

Skin, oral-care and nutricosmetic actives

No

APIs / fine chemicals

Patented and off-patent APIs from Hassan

No

Contract manufacturing

Utah facility services

No

Consumer wellness

AFI, Sanutra, Nature's Formulary

No

Income Statement

MetricFY2022

Revenue (INR Mn)

12,000

Estimate Details

Estimate (USD Mn)ValueProviderNote

Sami-Sabinsa Group Ltd annual revenue

158.7

Prospeo [S9]

Consistent with ₹1,200 crore at ~₹75–76/USD

Sabinsa (US) annual revenue range

100–500

Owler [S16]

Range only

Capex item (USD Mn)

Capex item (USD Mn)FY2020

Hassan API facility planned investment

30

Region Revenue (% of group)

Region Revenue (% of group)FY2022

Exports (all non-India)

95

India domestic

5

Region Overview

RegionAssessmentEvidence

North America

Largest and most mature market (inferred); management explicitly targeting expansion of US presence in 2026

US hiring of Director of Business Development; CEO Americas role [S30][S12]

Europe

Active expansion: offices in UK, France, Poland; President of European Operations appointed; Paris Knowledge Day 2026

[S23][S24][S37]

China / East Asia

Nanjing subsidiary relocated to new facility; Hi & Fi Asia-China 2026; Sabinsa on Wheels South Korea

[S23][S37]

Southeast Asia

Vitafoods Asia 2026 with APAC-specific regulatory positioning

[S21]

Africa

SAPHEX 2026 Johannesburg presence signals South African market development

[S37]

Australia / NZ

Sabinsa Australia with TGA listing effort

[S32]

India domestic

Small share (~5%) but founder called domestic market a growth opportunity; CEO keynote at Bharat Nutraverse 2026

[S10][S1]

Capital Markets

ItemStatus

Share price performance (1/3/5-yr)

Not applicable — private

External funding

None raised per Prospeo [S9]

IPO status

Announced intention (2022); no filing identified [S10]

Capital Markets Metric

FY2022

Analyst Conclusions

Management guidance: None published. Directional signals: US market expansion, consumer-brand growth, manufacturing build-out and partnerships [S8][S31].

Consensus: None (no coverage).

Bull case

  1. Defensible premium niche: a clinical-evidence moat (C3 Complex, BioPerine, LactoSpore) plus fresh 2026 data (Sabeet) supports pricing as regulators demand documentation.

  2. Integration upside: cultivation-to-consumer value chain allows margin capture as Sabinsa Wellness scales.

  3. Optionality: Hassan API capacity and a still-possible IPO could re-rate the group.

Bear case

  1. Commoditisation: management itself concedes customers trade down to cheaper supply.

  2. Concentration: ~95% export dependence and family-concentrated governance amplify trade and succession shocks.

  3. Execution drift: the 2020 revenue-doubling and 2022 IPO ambitions have no public evidence of delivery.

Catalysts and monitorables (next 12 months)

  • SupplySide Global, 28–30 October 2026: new ingredient launches and study announcements

  • Retail traction of Sabinsa Wellness brands

  • Any SEBI DRHP filing or strategic-investor announcement

  • Further acquisitions in consumer wellness

  • US tariff treatment of Indian botanical imports

  • Publication of additional clinical trials (women's health, liver, active nutrition)

  • Outcome of CSIR-NIIST collaboration discussions

Analyst verdict

Sabinsa Corporation is not the public company our list suggests; it is the US face of the privately held, Majeed family-controlled Sami-Sabinsa Group, and any assessment must be made through that lens. On the evidence available, the business is a credible, mid-sized, science-led specialist with an enviable portfolio of branded botanical ingredients — several of which effectively defined their categories in Western supplement markets — supported by a large patent estate, a substantial in-house scientific workforce and genuine vertical integration from field to extract.

The 2024 death of founder Dr. Muhammed Majeed was the most consequential event in the company's history. The succession to Dr. Anju Majeed and Dr. Shaheen Majeed appears orderly, and the new leadership has been more commercially assertive than its predecessor: it bought its first consumer brand within ten months, reorganised the Americas sales leadership, pushed into new geographies, and is positioning the company in growth themes such as women's health, longevity and active nutrition.

The constraints are equally clear. Sabinsa competes against multinationals many times its size and against low-cost producers, and management openly admits price-driven defections. Its export concentration exposes it to trade policy, and the move into finished goods risks irritating the very brand customers that buy its ingredients. Most importantly for an outside analyst, the absence of any audited financial disclosure since a single FY2022 revenue figure makes it impossible to test whether the heavy capital programme at Hassan has delivered the promised growth.

Our verdict: Sabinsa is a strategically sound, IP-rich franchise in a structurally growing market, best characterised as a "quality but opaque" counterparty. For partners and suppliers, risk is moderate. For any prospective investor, the critical unknowns — revenue trajectory since FY2022, margins, leverage and IPO timing — must be resolved through MCA filings or direct diligence before conviction can be formed.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenure / startBackgroundEducation

Dr. Anju Majeed

Group Executive Chairperson

Since 1 Apr 2024

Formerly Group Director and Senior Scientist; led API manufacturing, process R&D, pre-formulation, pilot plant teams

BS/MS Rutgers (microbiology, molecular genetics); MS Johns Hopkins; PhD Microbiology, Bharathidasan University; NIH Research Fellow 2001–05

Dr. Shaheen Majeed

Global CEO & Managing Director; board member

Since 1 Apr 2024

~25 years at Sabinsa (sales, supply chain, manufacturing, global marketing; 4 years President Worldwide); briefly CEO of three BGG World subsidiaries (HB Natural Ingredients USA, BGG Americas, Algae Health Sciences)

MBA; D.Litt. (honorary)

Asha Ramesh

CEO, Americas

CEO Sabinsa USA from Oct 2018; CEO Americas from Jan 2025

20+ years in group; previously VP Business Development; joined Sabinsa staff Jan 2000

—

P K Davé

CEO, Consumer Goods Division (Sabinsa Wellness)

Since Feb 2025

Founder/president of Nature's Formulary

—

Dr. Umar Jan

President, European Operations

———

Jan Obirek

VP Sales, US & Canada

Since Jan 2025

——

Madhu Subramanian

Global Business Expansion & Operations

———

Dr. K Srinivasa Reddy

Group Director, Quality & Regulatory

Re-joined (date not disclosed)

Former Director of Quality, OmniActive Health Technologies

—

Jeanette Fisher, RDN

Marketing Director

—

~20 years at Soft Gel Technologies

RDN

Darrin Fox

VP Operations, Sabinsa Utah

———

Dr. Alphons Philips

Director, Scientific Affairs

———

Brandon Prenger

Director of Business Development

2,026

20+ years: INS, SpecNova, Nutragenesis/Innophos, Deerland Enzymes, National Enzyme Co.

BS Animal Science, Southern Illinois University

Dr. Kalyanam Nagabhushanam

President, R&D (last reported)

—

Presented at FDA CDER Botanical Drug Seminar Series

—

“—” = not publicly disclosed.

Directors' Remuneration

ItemStatus

Executive compensation

Not publicly disclosed (no proxy statement)

Board composition / independence

Not publicly disclosed; Shaheen Majeed and Anju Majeed confirmed directors; Asha Ramesh joined Sabinsa (US) board in 2018 [S28]

Chair/CEO separation

Yes at group level — Executive Chairperson (Anju Majeed) separate from Global MD & CEO (Shaheen Majeed); both are siblings, so separation is not independence

Institutional ownership

None disclosed; company has "never raised funding" per Prospeo [S9]

Insider ownership

Believed majority family-controlled (Majeed family); exact stakes not publicly disclosed

Board & Management Changes

DateChangeContext

13 Mar 2024

Death of founder/chairman Muhammed Majeed

Key-person event after 36 years of leadership [S3]

1 Apr 2024

Anju Majeed Executive Chairperson; Shaheen Majeed Global MD & CEO

Second-generation succession [S7]

Jan 2025

Asha Ramesh CEO Americas; Jan Obirek VP Sales

Commercial reorganisation [S12]

Feb 2025

P K Davé CEO Consumer Goods

Integration of Nature's Formulary [S14]

2026

Brandon Prenger Director of Business Development

US growth push [S30]

Competitive Landscape

Key Competitors

CompetitorHQOwnershipOverlap with Sabinsa

OmniActive Health Technologies

India

Private

Curcumin, lutein, botanical actives

Naturex (part of Givaudan)

France/Switzerland

Listed (Givaudan)

Botanical extracts

Indena

Italy

Private

Botanical extracts incl. curcumin phytosome

Arjuna Natural

India

Private

Curcumin, ashwagandha

Natreon

USA/India

Private

Ayurvedic extracts (ashwagandha, amla)

dsm-firmenich (DSM)

Netherlands/Switzerland

Listed

Vitamins, nutrition ingredients

Roquette

France

Private

Plant-based ingredients

Ganeden (now Kerry)

Ireland

Listed (Kerry Group)

Bacillus coagulans probiotics vs LactoSpore

Novel Ingredient

USA

Private

Branded botanicals

SCD Probiotics

USA

Private

Probiotics

NOW Foods

USA

Private

Finished supplements (vs Sabinsa Wellness)

Garden of Life (Nestlé Health Science)

USA

Listed parent

Finished supplements

Competitor Detail

MetricSabinsa (group)

Revenue

~₹1,200 crore (FY2022, mgmt.)

Company Snapshot

$152.7M

Revenue

1,400

Employees

1988

Founded

New Jersey, US

Headquarters

SWOT Analysis

Strengths

  • IP depth: founder credited with over 500 US patents; IP team across US, Europe, Canada and India [S4][S6].
  • Clinical evidence base: C3 Complex positioned as the most clinically researched curcumin; new 2026 Sabeet trial [S1][S17].
  • Vertical integration: ~20,000-acre cultivation programme and eleven manufacturing facilities [S5][S7].
  • Scientific workforce: 120+ senior scientists [S5].
  • Regulatory assets: GRAS ingredients; EFSA-approved, REACH-registered tetrahydrocurcuminoids [S17][S22].
  • Recognition: ABC Varro E. Tyler Award 2023; USP reference-standards appreciation [S4][S23].

Weaknesses

  • Opacity: no public financials, limiting partner and investor confidence.
  • Scale: ~₹1,200 crore revenue (FY2022) versus multi-billion peers [S10].
  • Export concentration: ~95% of revenue from exports [S10].
  • Key-person/family concentration: leadership concentrated in founder's children since April 2024 [S7].
  • Price vulnerability: CEO acknowledged Sabinsa is sometimes passed over for lower-priced commodities [S13].
  • Unfulfilled IPO plan: 2022 two-year IPO target not met as of Oct 2026 [S10].

Opportunities

  • Consumer brands: three-brand Wellness platform and six retail SKUs (2025) [S18].
  • Women's health and longevity: Paris 2026 Knowledge Day and Sabeet trial [S1][S37].
  • India domestic market: only ~5% of revenue; CEO keynote at Bharat Nutraverse 2026 [S1][S10].
  • APIs: Hassan facility designed for patented and off-patent APIs [S26].
  • New geographies: South Africa (SAPHEX), South Korea, Southeast Asia [S21][S37].
  • AI-accelerated clinical research: stated management interest [S21].

Threats

  • Commoditisation: low-cost curcumin and ashwagandha competition [S13].
  • Patent expiry / infringement: recurring need to litigate (four D.N.J. suits) [S25].
  • Probiotic competition: Kerry's GanedenBC30 versus LactoSpore [S16].
  • Channel conflict: Wellness brands may compete with Sabinsa's own B2B customers.
  • Trade policy: US import tariffs on Indian goods affect an export-heavy model.
  • Regulatory tightening: heightened global safety scrutiny on botanicals, noted by management in 2026 [S34].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Jan 2025Asha Ramesh named CEO Americas; Jan Obirek VP Sales US & Canada [S12]Commercial restructuring
3 Feb 2025Nature's Formulary acquired; P K Davé heads consumer goods [S13]First downstream acquisition
27 Aug 2025Sabinsa Wellness brings Sanutra and AFI to retail alongside Nature's Formulary [S16]Consumer launch
2 Sep 2025Six Sabinsa Wellness products introduced to retail [S18]Consumer expansion
10 Feb 2026Expo West 2026 programme announced (ingredients + Wellness) [S17]Go-to-market
3–6 Mar 2026Exhibits at Natural Products Expo West, Anaheim (Booths 4113, 3305) [S39]Key US trade show
11 Mar 2026Anju Majeed visits CSIR-NIIST to explore collaboration [S37]R&D partnerships
12 Mar 2026Knowledge Day on Longevity & Women's Health, Paris [S37]European market development
25–26 Mar 2026SAPHEX 2026, Johannesburg: Curcumin C3 Reduct, LactoSpore, Saberry, Sabeet, Cococin, PoZibio [S37]Africa market entry signal
31 Mar 2026CEO Americas interview on clinical validation and regulatory readiness (LivLonga) [S34]Positioning
Apr 2026Sabinsa on Wheels announced for South Korea; web seminars on LactoSpore and weight management [S10b]Asia education campaign
22 Jun 2026Hi & Fi Asia-China 2026 participation [S37]China commercial
Jul 2026Sabeet clinical trial in postmenopausal women published [S1]New clinical claim
2026 (by Aug)Brandon Prenger named Director of Business Development [S30]US growth
27 Aug 2026Announces seven September 2026 events [S1]Commercial intensity
2–4 Sep 2026Vitafoods Asia, Bangkok (booth H6-J55); CEO on AI clinical-trials panel [S21]APAC positioning
7–9 Sep 2026Bharat Nutraverse Expo, New Delhi; CEO opening keynote [S1]India domestic push
24 Sep 2026Sponsors The Outlook on Active Nutrition, East Windsor [S1]Active-nutrition category
28–30 Oct 2026 (upcoming)SupplySide Global, Las Vegas [S35]Upcoming catalyst

Product Offering

  • Sabinsa Corporation
    • Probiotics

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Region (%): Exports (all non-India) was 95% in FY2022.
Sabinsa Corporation — Revenue by Region (%)
Series (%)FY2022
Exports (all non-India)95
India domestic5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1Nutritional Outlook — "Sabinsa Sets Seven-Event September Schedule…" (nutritionaloutlook.com) — 31 Aug 2026
  2. S2CB Insights — Sabinsa company profile ( — Accessed Oct 2026 (cbinsights.com)
  3. S3Vitamin Retailer — Sabinsa Corporation tag page (founder death; Wellness launch) — 2024–2025
  4. S4Happi — "Sabinsa Celebrates 35th Anniversary…" — 2023
  5. S5Happi — founder obituary (sales, facilities, employees, countries) — 13 Mar 2024
  6. S6New Hope Network — "Muhammed Majeed, founder of Sami-Sabinsa Group, dies at 75" — Apr 2024
  7. S7SOFW / NIE Magazine — Sami-Sabinsa leadership announcements — Apr 2024
  8. S8Nutritional Outlook — 2024 Best of the Industry Awards: Shaheen Majeed — 2024
  9. S9Prospeo — Sami-Sabinsa Group Limited profile (estimates) — Accessed Oct 2026
  10. S10sabinsa.com — Hindu BusinessLine reprint, "Nutraceutical EOU Sami-Sabinsa to invest ₹300 crore…" — 14 Jul 2022
  11. S10bsabinsa.com media coverage listings (Sabinsa on Wheels Korea; web seminars) — Apr 2026
  12. S11sabinsa.com — Times Business Awards press release — Jul 2024
  13. S12Nutritional Outlook — "Sabinsa announces it has acquired Ayurvedic brand Nature's Formulary" — 3 Feb 2025
  14. S13NutraIngredients — "Sabinsa acquires Ayurvedic brand Nature's Formulary" — 3 Feb 2025
  15. S14New Hope Network — Nature's Formulary acquisition — 6 Feb 2025
  16. S15NIE Magazine — "Sami-Sabinsa Group Announces New Leadership Positions" — Apr 2024
  17. S16Owler — Sabinsa profile and competitor list — Accessed Oct 2026
  18. S16bCB Insights — Sabinsa acquisitions/competitors page — Accessed Oct 2026
  19. S17sabinsa.com — Expo West 2026 press release — Feb 2026
  20. S18Vitamin Retailer — "Sabinsa Wellness Brings 3 Consumer Brands to Retail" — 2 Sep 2025
  21. S19Nutritional Outlook — six Sabinsa Wellness products introduced to retail — 2025
  22. S20Nutritional Outlook — Expo West 2026 preview — 17 Feb 2026
  23. S21sabinsa.com — Vitafoods Asia 2026 press release — Aug 2026
  24. S22sabinsa.com — in-cosmetics Paris 2024 event page — 2024
  25. S23NIE Magazine — Sabinsa tag page (Nanjing, France, Hassan, USP, UK) — 2023–2026
  26. S24NIE Magazine — Sabinsa tag page 2 (Poland, Chemill, KCP Biotech, ForsLean) — Various
  27. S25SupplySide Supplement Journal — "Sabinsa Files 4 Intellectual Property Infringement…" — Undated
  28. S26Nutraceuticals World — Hassan ground-breaking — Feb 2020
  29. S27NIE Magazine — "Sami Labs Breaks Ground on $30M Production Facility" — 12 Feb 2020
  30. S28Happi — Asha Ramesh promoted to CEO Sabinsa USA — 1 Oct 2018
  31. S29Cosmetics & Toiletries — "Sabinsa Makes US and Brazilian Staff Updates" — Undated
  32. S30Nutritional Outlook — "Sabinsa Names Brandon Prenger as Director of Business Development" — 2026
  33. S31Nutraceuticals World / Nutraceutical Business Review — Prenger appointment — 2026
  34. S32New Hope Network — "Sabinsa Australia announces 2 key hires" — Undated
  35. S33WholeFoods Magazine — Sabinsa keyword archive (COVID RCT, oral health) — Various
  36. S34Nutritional Outlook — Asha Ramesh on clinical validation (LivLonga) — 31 Mar 2026
  37. S35Nutraceuticals World — SupplySide West preview (pTeroSol, NiLitis, Sabeet) — 2016 / page dated 2026
  38. S36WholeFoods Magazine — Macumax eye-health study — Undated
  39. S37sabinsa.com — "Sabinsa Shines at SAPHEX 2026" event page — Mar 2026
  40. S38drmajeed.com — Hassan facility press release (ZLD; PMMI market data) — Jan 2020
  41. S39sabinsa.com — Expo West 2026 event recap — Mar 2026
  42. S40Cosmetics & Toiletries — Sami Labs/Sabinsa company page (O2 Renewable Energy; Majeed Foundation) — Various

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.